Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PainchekASX:PCK -4.55%40 3-Year EBITDA Growth Rate is 7.60% as of Dec. 2025, which is 60% below its 10-year median of 19.10. GuruFocus rates ASX:PCK with a GF Score™ of 40/100 and a GF Value™ of A$0.41 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 524 Healthcare Providers & Services companies, Painchek ranks worse than 55.73% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 15.50% per year.
During the past 10 years, the average EBITDA Per Share Growth Rate was 7.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Painchek was 46.90% per year. The lowest was -25.20% per year. And the median was 19.10% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Painchek 3-Year EBITDA Growth Rate Related Terms
ASX:PCK vs VEEV, BTSG, TEM: 3-Year EBITDA Growth Rate Comparison
For the Health Information Services subindustry, Painchek's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Painchek 3-Year EBITDA Growth Rate vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Painchek's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Painchek's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 7.60% mean?
Painchek (ASX:PCK) has a 3-Year EBITDA Growth Rate of 7.60% as of Dec. 2025. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Painchek and its competitors. This is 60% below median its historical median of 19.10. According to the industry distribution chart, Painchek ranks #292 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 55.7%.
Is Painchek's 3-Year EBITDA Growth Rate too high?
Painchek's current 3-Year EBITDA Growth Rate of 7.60% is 60% below median its 10-year median of 19.10. The Healthcare Providers & Services industry median 3-Year EBITDA Growth Rate is 10.25. Painchek's value of 7.60% is 25.9% below this industry median. Based on the distribution chart, Painchek ranks #292 out of 524 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Painchek has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Painchek's 3-Year EBITDA Growth Rate compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Painchek ranks #292 out of 524 companies for 3-Year EBITDA Growth Rate. This places Painchek in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 10.25. Painchek's value of 7.60% is 25.9% below this benchmark. While the company's 10-year median is 19.10 vs. the industry median of 10.25, Painchek has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Healthcare Providers & Services company?
The median 3-Year EBITDA Growth Rate among Healthcare Providers & Services companies is 10.25, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Painchek's current 3-Year EBITDA Growth Rate of 7.60% is 25.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Painchek and its competitors. For the Healthcare Providers & Services industry, the median 3-Year EBITDA Growth Rate is 10.25 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Painchek's current 3-Year EBITDA Growth Rate is 7.60%, which is 60% below median its own 10-year median of 19.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Painchek stock overvalued right now?
Based on GuruFocus' analysis, Painchek (ASX:PCK) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.41, compared to a current price of A$0.11 — trading 74.4% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 7.60%, which is 60% below median its 10-year median of 19.10 and 25.9% below the Healthcare Providers & Services industry median of 10.25. Painchek's overall GF Score™ is 40/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Painchek (ASX:PCK), the current 3-Year EBITDA Growth Rate is 7.60% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Painchek (ASX:PCK) Overvalued in 2026?
Based on GuruFocus' analysis, Painchek stock appears to be undervalued.
The current stock price of A$0.11 is trading 74.4% below its estimated GF Value™ of A$0.41.
GuruFocus considers Painchek to be Possible Value Trap.
Key valuation signals for ASX:PCK:
3-Year EBITDA Growth Rate: 7.60% (60% below median its 10-year median of 19.10)
GF Value™: A$0.41 vs. price of A$0.11 (74.4% below fair value)
Industry Position: 25.9% below the Healthcare Providers & Services median (#292 of 524)
No single metric tells the full story. See the ASX:PCK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Painchek Ltd is engaged in the development and commercialization of mobile medical device applications that provide pain assessment for individuals who are unable to communicate pain with carers. It operates in one segment, namely the sale of its pain assessment solutions. Its geographic segments include Australia, the United Kingdom, and Other countries, of which it generates the majority of its revenue from Australia.
40GF Score
Get the complete analysis for ASX:PCK
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:PCK has been successfully added to your 
